Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Net Income (2016 - 2025)

Historic Net Income for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$33.3 million.

  • UroGen Pharma's Net Income fell 4086.51% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.6 million, marking a year-over-year decrease of 4269.79%. This contributed to the annual value of -$126.9 million for FY2024, which is 2408.94% down from last year.
  • UroGen Pharma's Net Income amounted to -$33.3 million in Q3 2025, which was down 4086.51% from -$49.9 million recorded in Q2 2025.
  • UroGen Pharma's Net Income's 5-year high stood at -$21.9 million during Q3 2023, with a 5-year trough of -$49.9 million in Q2 2025.
  • For the 5-year period, UroGen Pharma's Net Income averaged around -$30.4 million, with its median value being -$28.5 million (2021).
  • In the last 5 years, UroGen Pharma's Net Income skyrocketed by 1635.46% in 2021 and then tumbled by 4950.75% in 2025.
  • UroGen Pharma's Net Income (Quarter) stood at -$28.5 million in 2021, then dropped by 1.47% to -$28.9 million in 2022, then grew by 9.88% to -$26.0 million in 2023, then plummeted by 44.19% to -$37.5 million in 2024, then grew by 11.1% to -$33.3 million in 2025.
  • Its Net Income was -$33.3 million in Q3 2025, compared to -$49.9 million in Q2 2025 and -$43.8 million in Q1 2025.